These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30030904)

  • 1. Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study.
    Carlson JJ; Kim DD; Guzauskas GF; Bennette CS; Veenstra DL; Basu A; Hendrix N; Hershman DL; Baker L; Ramsey SD
    Cancer Med; 2018 Sep; 7(9):4251-4260. PubMed ID: 30030904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.
    Bennette CS; Veenstra DL; Basu A; Baker LH; Ramsey SD; Carlson JJ
    Med Decis Making; 2016 Jul; 36(5):641-51. PubMed ID: 27012232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Care Research Team Assessment (PCRTA): development and evaluation.
    Carter YH; Shaw S; Macfarlane F
    Occas Pap R Coll Gen Pract; 2002 Feb; (81):iii-vi, 1-72. PubMed ID: 12049028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of NCI-mandated scientific review on protocol development and content.
    Ning N; Yan J; Xie XJ; Gerber DE
    J Natl Compr Canc Netw; 2015 Apr; 13(4):409-16. PubMed ID: 25870377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies.
    Deverka PA; Bangs R; Kreizenbeck K; Delaney DM; Hershman DL; Blanke CD; Ramsey SD
    J Natl Cancer Inst; 2018 Jun; 110(6):553-559. PubMed ID: 29684151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of a Centralized Clinical Trials Coverage Analysis: A Joint Initiative of the American Society of Clinical Oncology and the National Cancer Institute.
    Szczepanek CM; Hurley P; Good MJ; Denicoff A; Willenberg K; Dawson C; Kurbegov D
    J Oncol Pract; 2017 Jun; 13(6):395-400. PubMed ID: 28481681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 2008 William M. Feinberg lecture: prioritizing stroke research.
    Johnston SC
    Stroke; 2008 Dec; 39(12):3431-6. PubMed ID: 18818399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III clinical trial development: a process of chutes and ladders.
    Dilts DM; Cheng SK; Crites JS; Sandler AB; Doroshow JH
    Clin Cancer Res; 2010 Nov; 16(22):5381-9. PubMed ID: 21062928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria for the use of omics-based predictors in clinical trials.
    McShane LM; Cavenagh MM; Lively TG; Eberhard DA; Bigbee WL; Williams PM; Mesirov JP; Polley MY; Kim KY; Tricoli JV; Taylor JM; Shuman DJ; Simon RM; Doroshow JH; Conley BA
    Nature; 2013 Oct; 502(7471):317-20. PubMed ID: 24132288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposed new clinical trial system at NCI gets mixed reviews.
    Nicholas J
    J Natl Cancer Inst; 2011 Feb; 103(4):292-5. PubMed ID: 21303997
    [No Abstract]   [Full Text] [Related]  

  • 13. NCI, Cooperative Groups gear up for changes in clinical trials system: new policies initiated in response to institute of medicine report.
    Printz C
    Cancer; 2011 May; 117(10):2017-9. PubMed ID: 21523709
    [No Abstract]   [Full Text] [Related]  

  • 14. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.
    Unger JM; Barlow WE; Tangen CM; Ramsey SD; Thompson IM; Klein EA; LeBlanc M; Blanke CD; Goodman PJ; Minasian LM; Nghiem VT; Hershman DL
    Cancer Epidemiol; 2018 Aug; 55():117-122. PubMed ID: 29936140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NCI Cancer Imaging Program efforts and their application to non-conventional radionuclides.
    Croft BY
    Q J Nucl Med Mol Imaging; 2008 Jun; 52(2):107-10. PubMed ID: 18043543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. United States military contributions to the National Cancer Institute.
    Sarvis JA; Thompson IM
    Urol Oncol; 2009; 27(5):558-61. PubMed ID: 19720303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An equity lens can ensure an equity-oriented approach to agenda setting and priority setting of Cochrane Reviews.
    Nasser M; Ueffing E; Welch V; Tugwell P
    J Clin Epidemiol; 2013 May; 66(5):511-21. PubMed ID: 23477991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model for making project funding decisions at the National Cancer Institute.
    Hall NG; Hershey JC; Kessler LG; Stotts RC
    Oper Res; 1992; 40(6):1040-52. PubMed ID: 10123313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Institute of Medicine, the National Cancer Institute, and clinical trials.
    Cox JD
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1285-6. PubMed ID: 21414512
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.